A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation
出版年份 2019 全文链接
标题
A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation
作者
关键词
-
出版物
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 38, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-05-22
DOI
10.1186/s13046-019-1207-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia
- (2018) Yiran Chen et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
- (2018) Shang-Gin Wu et al. Molecular Cancer
- A dual-function epidermal growth factor receptor pathway substrate 8 (Eps8)-derived peptide exhibits a potent cytotoxic T lymphocyte-activating effect and a specific inhibitory activity
- (2018) Xiaoling Xie et al. Cell Death & Disease
- Acute toxic effects of ruthenium (II)/amino acid/diphosphine complexes on Swiss mice and zebrafish embryos
- (2018) Francyelli Mello-Andrade et al. BIOMEDICINE & PHARMACOTHERAPY
- Functional role of RRS1 in breast cancer cell proliferation
- (2018) Jinlian Song et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer
- (2016) Haa-Na Song et al. Journal of Thoracic Oncology
- Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer
- (2015) Masaru Matsumoto et al. BMC CANCER
- The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
- (2015) M. J. Niederst et al. CLINICAL CANCER RESEARCH
- Therapeutic applications of the cell-penetrating HIV-1 Tat peptide
- (2015) Mafalda Rizzuti et al. DRUG DISCOVERY TODAY
- Identification of the receptor tyrosine kinases (RTKs)-oriented functional targets of miR-206 by an antibody-based protein array
- (2015) Yazhou Cui et al. FEBS LETTERS
- Silencing of Eps8 inhibits in vitro angiogenesis
- (2015) Elisa Cappellini et al. LIFE SCIENCES
- In Vivo Efficacy and Toxicity Studies of a Novel Antibacterial Agent: 14-O-[(2-Amino-1,3,4-thiadiazol-5-yl)Thioacetyl] Mutilin
- (2015) Chao Zhang et al. MOLECULES
- A HLA-A2-restricted CTL epitope induces anti-tumor effects against human lung cancer in mouse xenograft model
- (2015) Yuh-Pyng Sher et al. Oncotarget
- Acquired Resistance ofEGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor
- (2015) Helena A. Yu et al. JAMA Oncology
- Eps8 regulates cellular proliferation and migration of breast cancer
- (2014) CHENG CHEN et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Influence of Macrocyclization on Allosteric, Juxtamembrane-Derived, Stapled Peptide Inhibitors of the Epidermal Growth Factor Receptor (EGFR)
- (2014) Julie K.-L. Sinclair et al. ORGANIC LETTERS
- ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
- (2014) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex
- (2013) C. Gao et al. BLOOD
- Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer
- (2013) D. Park et al. CANCER RESEARCH
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- 5S Ribosomal RNA Is an Essential Component of a Nascent Ribosomal Precursor Complex that Regulates the Hdm2-p53 Checkpoint
- (2013) Giulio Donati et al. Cell Reports
- The regulatory role of the juxtamembrane region in the activity of the epidermal growth factor receptor
- (2012) Aislyn D.W. Boran BIOCHEMICAL SOCIETY TRANSACTIONS
- Silencing of Eps8 blocks migration and invasion in human glioblastoma cell lines
- (2012) Maria Grazia Cattaneo et al. EXPERIMENTAL CELL RESEARCH
- Eps8 promotes cellular growth of human malignant gliomas
- (2012) XIAOFENG DING et al. ONCOLOGY REPORTS
- A Potential Peptide Therapeutic Derived from the Juxtamembrane Domain of the Epidermal Growth Factor Receptor
- (2012) Aislyn D. W. Boran et al. PLoS One
- The origins of cancer robustness and evolvability
- (2010) Tianhai Tian et al. Integrative Biology
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR Signaling and Drug Discovery
- (2010) Georg Lurje et al. ONCOLOGY
- The Juxtamembrane Region of EGFR Takes Center Stage
- (2009) Stevan R. Hubbard CELL
- Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment
- (2009) Natalia Jura et al. CELL
- The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain
- (2009) Monica Red Brewer et al. MOLECULAR CELL
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidermal Growth Factor Receptor Pathway Substrate 8 Is Overexpressed in Human Pituitary Tumors: Role in Proliferation and Survival
- (2008) Mei Xu et al. ENDOCRINOLOGY
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started